Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Expenses (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Operating Expenses for 14 consecutive years, with $29.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 11.57% year-over-year to $29.4 million, compared with a TTM value of $116.1 million through Dec 2025, down 0.91%, and an annual FY2025 reading of $116.1 million, down 0.91% over the prior year.
  • Operating Expenses was $29.4 million for Q4 2025 at Heron Therapeutics, down from $30.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $86.4 million in Q1 2022 and bottomed at $26.4 million in Q4 2024.
  • Average Operating Expenses over 5 years is $49.0 million, with a median of $38.0 million recorded in 2022.
  • Peak annual rise in Operating Expenses hit 19.75% in 2022, while the deepest fall reached 49.11% in 2022.
  • Year by year, Operating Expenses stood at $74.2 million in 2021, then crashed by 49.11% to $37.8 million in 2022, then fell by 8.44% to $34.6 million in 2023, then fell by 23.69% to $26.4 million in 2024, then grew by 11.57% to $29.4 million in 2025.
  • Business Quant data shows Operating Expenses for HRTX at $29.4 million in Q4 2025, $30.4 million in Q3 2025, and $29.0 million in Q2 2025.